Filgrastim biosimilar - Ratiopharm/Teva

Drug Profile

Filgrastim biosimilar - Ratiopharm/Teva

Alternative Names: Biograstim (Teva); Filgrastim BS Inj.; Filgrastim NK; Granix; Leucocyte growth factor - Teva; Leukocyte growth factor - Teva; Neutroval™; Ratiograstim; Short-acting G-CSF - Teva; Short-acting Granulocyte Colony Stimulating Factor - Teva; tbo-filgrastim; Tevagrastim; XM-02; XM02-filgrastim

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ratiopharm; SICOR Biotech UAB
  • Developer Nippon Kayaku; Ratiopharm; SICOR Biotech UAB; Teva Pharmaceutical Industries; Teva Pharmaceuticals Europe; Teva-KOWA-Pharma
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 08 Nov 2017 Teva Pharmaceutical Industries terminates the phase III GRANIX trial in Healthy volunteers due to low enrolment in USA (SC) (NCT03029000)
  • 10 May 2017 Teva Pharmaceutical Industries initiates enrolment in the phase III GRANIX trial in Healthy volunteers in USA (SC) (NCT03029000)
  • 04 Apr 2017 Teva Pharmaceutical completes a phase II trial in Neutropenia (In infants, In children, In adolescents) in USA, Hungary, Poland, Russia, Ukraine, Bulgaria, Croatia, Romania and Serbia (NCT02190721)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top